Navigation Links
BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
Date:3/9/2011

RALEIGH, N.C., March 9, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, California.  The presentation is scheduled for Monday, March 14 at 9:00 A.M. Pacific Time.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Dr. Sirgo will focus on BDSI's product pipeline, with a particular focus on BEMA Buprenorphine for the treatment of chronic pain and opioid dependence.  

The presentation will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, the presentation will be archived for 3 months.

About BioDelivery Sciences International

BioDelivery Sciences International (Nasdaq: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby ... air to his lungs. April and Bryan Gionfriddo ... predictions weren,t true. "Quite a few doctors said ... alive," says April Gionfriddo , about her ... Anything that would work, we would take it and run ...
(Date:5/23/2013)... May 23, 2013  Spring Bank Pharmaceuticals, Inc., a ... viral infections, today announced that it has initiated dosing ... investigational, once daily, oral therapy for the treatment of ... patients and is designed to assess both the safety ... a first-in-class drug for the treatment of chronic HCV ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... 13, 2011 Reportlinker.com announces that a new market ... UCB S.A.: PharmaVitae Profile ... This analysis examines the historical and forecast performance ... encompasses global company strategy, portfolio and pipeline analysis and ...
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... the Zimmer NexGen LPS-Flex Mobile Bearing ... the United States.  The LPS-Flex Mobile Bearing knee provides a ... cruciate ligament (ACL), replicating the anatomic center of knee rotation. ...
Cached Medicine Technology:Reportlinker Adds UCB S.A.: PharmaVitae Profile 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 2Zimmer Introduces a Move Forward in Mobile Bearing Knee Design 3
(Date:5/24/2013)... This week is National EMS Week, which ... provide the best emergency care and to improve health ... also to educate the public that all can play ... the first link, and a very important one. According ... a cardiac arrest can triple a victim’s chance of ...
(Date:5/24/2013)... hospitalized for heart failure appear to have better odds ... the morning, a new study finds. Death rates ... patients admitted in January, on Fridays and overnight, according ... findings Saturday in Portugal at the annual meeting of ... Cardiology. "The fact that patients admitted right ...
(Date:5/24/2013)... Florida (PRWEB) May 24, 2013 KC and ... the Title Sponsors for FreeRide836. Their oldest sons, Kyle and ... and Tracey Russell family and several professional kiteboarders. , KC ... amazing project. "This has miraculously come together such that virtually ... able to participate." , 20 kite boarders will meet at ...
(Date:5/24/2013)... May 24 (HealthDay News) -- New research suggests ... among people with insomnia. Every additional hour ... 72 percent drop in the likelihood of moderate ... from the University of Pennsylvania. "We ... between sleep duration and suicide risk," study author, ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Gift ... Cards, major competitors in sustainable card material, are ... using forest materials as a sustainable gift card ... to identify industry challenges and increase education and ... programs to support the reduction of carbon footprint ...
Breaking Medicine News(10 mins):Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 2Health News:Making Gift Cards Greener- Competitors Combine Efforts to Educate and Empower Merchants 3
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
... good models for human biology and disease. Now, ... that is transparent throughout its life. The new ... and observe processes like tumor metastasis and blood production ... fish, described in the February 7 issue of Cell ...
... Prescription pediatric drugs represent,an enormous market, with manufacturer sales ... forecast at a modest 3.2%, reaching $43,billion by 2011, ... 11.7%, is,expected to achieve the highest growth rate of ... new report The World Market for,Pediatric Drugs., The ...
... N.C., Feb. 6 With pharmaceutical sales,forces shrinking ... force will be a key driver in organizational ... structure conducive to motivating sales people,properly communicating goals ... both,organizational and personal goals., The Best Practice ...
... 6 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... been dosed in its Phase Ib, multi-center, open-label,ascending ... candidate,CD-NP, a novel chimeric natriuretic peptide, in development ... "We are very excited that dosing has begun ...
... to seek restatement of Beth Israel Deaconess,Medical Center audit, ... Douglas T. Linde should apply the same Sarbanes-Oxley,standards used ... role on the board of Beth Israel Deaconess Medical ... Workers East. Linde is,also the president and CFO of ...
Cached Medicine News:Health News:Senetek PLC Announces Launch of New Website 2Health News:Transparent fish to make human biology clearer 2Health News:Transparent fish to make human biology clearer 3Health News:Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs 2Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 2Health News:Nile Therapeutics Announces Dosing of First Heart Failure Patient in Phase Ib Study of CD-NP 3Health News:Boston Properties Executive and Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: